10-QPeriod: Q1 FY2003

CVS HEALTH Corp Quarterly Report for Q1 Ended Mar 29, 2003

Filed May 12, 2003For Securities:CVS

Summary

CVS Corporation reported strong first-quarter 2003 results, with net sales increasing by 5.7% to $6.3 billion and net earnings growing by 11.7% to $196.3 million. This growth was primarily driven by robust performance in the Retail Pharmacy segment, which benefited from favorable industry trends like an aging population and increased pharmaceutical utilization. The company also saw improvements in gross margin as a percentage of net sales, reaching 25.4%, up from 25.0% in the prior year, attributed to better inventory management and a higher proportion of sales from generic drugs. Financially, CVS demonstrated improved operational cash flow, up significantly from $49.7 million to $183.6 million, largely due to better working capital management. While investing activities showed a net outflow, this was lower than the previous year, primarily due to reduced capital expenditures on property and equipment. The company ended the quarter with a solid cash position and adequate liquidity, supported by its operating cash flows and credit facilities, indicating a stable financial outlook for the near future.

Key Highlights

  • 1Net sales increased by 5.7% to $6.3 billion for the 13 weeks ended March 29, 2003.
  • 2Net earnings grew by 11.7% to $196.3 million, resulting in diluted EPS of $0.48.
  • 3Gross margin increased to 25.4% of net sales, up from 25.0% in the prior year, driven by improved inventory management and higher generic drug sales.
  • 4Net cash provided by operating activities significantly increased by $133.9 million to $183.6 million.
  • 5The Retail Pharmacy segment remains the primary revenue driver, with strong pharmacy sales growth contributing to overall performance.
  • 6Operating profit increased by 11.7% to $331.3 million.
  • 7The company ended the quarter with $648.1 million in cash and cash equivalents.

Frequently Asked Questions

Sales growth was driven by continued strength in the Retail Pharmacy segment, benefiting from favorable demographic trends such as an aging population and increased use of pharmaceuticals. Higher pharmacy sales, particularly from managed care customers, and industry-wide trends contributed positively. Pharmacy sales represented 69.4% of total sales, up from 67.4% in the prior year.

Gross margin as a percentage of net sales improved to 25.4% from 25.0% in the prior year. This improvement was attributed to lower markdowns, better seasonal sell-through, and the increasing contribution of generic drugs, which typically carry higher gross margins. Efforts to renegotiate or drop unprofitable third-party programs also helped improve reimbursement rates.

CVS demonstrated improved financial health, with net cash provided by operating activities increasing substantially to $183.6 million. The company ended the quarter with $648.1 million in cash and cash equivalents. Management believes that current cash on hand, operating cash flows, and access to financing through credit facilities are sufficient to cover working capital needs, capital expenditures, and debt service for the next twelve months and the foreseeable future.

The adoption of Emerging Issues Task Force release Issue No. 02-16, 'Accounting by a Reseller for Cash Consideration Received from a Vendor,' effective December 29, 2002, resulted in a $4.8 million reduction in net earnings for the first quarter of 2003. This pronouncement requires vendor allowances to be treated as a reduction in inventory costs unless specifically identified as reimbursement for other services.